Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
Publication
, Journal Article
Meriggioli, MN; Ciafaloni, E; Al-Hayk, KA; Rowin, J; Tucker-Lipscomb, B; Massey, JM; Sanders, DB
Published in: Neurology
November 25, 2003
The authors report a retrospective analysis of the use of mycophenolate mofetil (MyM) in 85 patients with autoimmune myasthenia gravis. The Myasthenia Gravis Foundation of America (MGFA) postintervention status (PIS) was used to characterize the treatment response in each patient. Sixty-two patients (73%) achieved a PIS status indicating improvement. Quantitative strength testing performed on the majority of patients before and after treatment also improved. Side effects to MyM were observed in 27% of patients but required discontinuation in only 6%.
Duke Scholars
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
November 25, 2003
Volume
61
Issue
10
Start / End Page
1438 / 1440
Location
United States
Related Subject Headings
- Treatment Outcome
- Retrospective Studies
- Neurology & Neurosurgery
- Mycophenolic Acid
- Myasthenia Gravis
- Middle Aged
- Male
- Immunosuppressive Agents
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Meriggioli, M. N., Ciafaloni, E., Al-Hayk, K. A., Rowin, J., Tucker-Lipscomb, B., Massey, J. M., & Sanders, D. B. (2003). Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology, 61(10), 1438–1440. https://doi.org/10.1212/01.wnl.0000094122.88929.0b
Meriggioli, M. N., E. Ciafaloni, K. A. Al-Hayk, J. Rowin, B. Tucker-Lipscomb, J. M. Massey, and D. B. Sanders. “Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.” Neurology 61, no. 10 (November 25, 2003): 1438–40. https://doi.org/10.1212/01.wnl.0000094122.88929.0b.
Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25;61(10):1438–40.
Meriggioli, M. N., et al. “Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.” Neurology, vol. 61, no. 10, Nov. 2003, pp. 1438–40. Pubmed, doi:10.1212/01.wnl.0000094122.88929.0b.
Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25;61(10):1438–1440.
Published In
Neurology
DOI
EISSN
1526-632X
Publication Date
November 25, 2003
Volume
61
Issue
10
Start / End Page
1438 / 1440
Location
United States
Related Subject Headings
- Treatment Outcome
- Retrospective Studies
- Neurology & Neurosurgery
- Mycophenolic Acid
- Myasthenia Gravis
- Middle Aged
- Male
- Immunosuppressive Agents
- Humans
- Female